Founded in 2019, Symray Biopharma is a biotechnology company focused on the innovative R&D and clinical translation of antibody-based biologics. The company was recognized as a Shanghai “Specialized, Refined, Distinctive and Innovative” (SRDI) enterprise in 2022 and holds National High-Tech Enterprise status. Guided by clinical value, Symray leverages an antibody discovery platform covering all species, all epitopes and all functions, a high-throughput, automated antibody characterization platform, and a systematic, tailored drug validation platform to develop a series of therapeutic modalities, including monoclonal antibodies, bispecific antibodies, ADCs and antibody fusion proteins.
With the mission of “establishing a new paradigm for innovative biologics R&D”, Symray Biopharma is committed to connecting innovators across the pharmaceutical R&D value chain — offering scientists a platform for translational innovation and pharmaceutical companies with differentiated, high-quality pipelines. The company currently has 30+ pipeline programs, 200+ targets under development and 20+ external collaborations. A highly experienced R&D team, mature technology platforms and an extensive off-the-shelf product portfolio enable us to stand out in a highly competitive market.